These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34034691)

  • 1. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
    Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
    BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
    Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
    Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
    Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
    Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
    Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
    World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
    Takahara K; Naiki T; Ito T; Nakane K; Koie T; Yasui T; Miyake H; Shiroki R
    Int J Urol; 2022 Mar; 29(3):229-234. PubMed ID: 34863085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
    Ozaki K; Hatakeyama S; Narita S; Hata K; Yanagisawa T; Tanaka T; Togashi K; Hamaya T; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Kimura T; Habuchi T; Ohyama C
    World J Urol; 2023 Jan; 41(1):67-75. PubMed ID: 36520204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
    Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Habuchi T
    Int J Clin Oncol; 2022 Sep; 27(9):1477-1486. PubMed ID: 35748967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of Abiraterone Acetate Plus Prednisolone and Combined Androgen Blockade in High-risk Metastatic Hormone-Sensitive Prostate Cancer].
    Yasukawa H; Ikehata Y; Tsuboi Y; Nishiyama N; Watanabe A; Fujiuchi Y; Kitamura H
    Hinyokika Kiyo; 2020 Dec; 66(12):427-432. PubMed ID: 33435652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
    Tsaur I; Heidegger I; Bektic J; Kafka M; van den Bergh RCN; Hunting JCB; Thomas A; Brandt MP; Höfner T; Debedde E; Thibault C; Ermacora P; Zattoni F; Foti S; Kretschmer A; Ploussard G; Rodler S; von Amsberg G; Tilki D; Surcel C; Rosenzweig B; Gadot M; Gandaglia G; Dotzauer R;
    Cancer Med; 2021 Sep; 10(18):6354-6364. PubMed ID: 34374489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
    Kanao K; Takahashi T; Umezawa Y; Okabe T; Kaneko G; Shirotake S; Nishimoto K; Oyama M
    PLoS One; 2022; 17(10):e0276081. PubMed ID: 36264927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
    Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
    Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
    Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L; Shohdy KS; Abdel-Rahman O
    Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
    Ueda T; Shiraishi T; Ito S; Ohashi M; Matsugasumi T; Yamada Y; Fujihara A; Hongo F; Okihara K; Ukimura O
    Sci Rep; 2021 May; 11(1):10094. PubMed ID: 33980956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
    Smith KER; Brown JT; Wan L; Liu Y; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O; Carthon B; Nazha B; Bilen MA
    Oncologist; 2021 Nov; 26(11):956-964. PubMed ID: 34096667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Miura Y; Hatakeyama S; Narita S; Kimura T; Hata K; Yanagisawa T; Tanaka T; Ishi N; Kawamura S; Hoshi S; Ishidoya S; Mitsuzuka K; Ito A; Tsuchiya N; Egawa S; Habuchi T; Ohyama C
    Prostate; 2022 Sep; 82(13):1304-1312. PubMed ID: 35747992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.